&lt;p&gt;Ruxolitinib In The Treatment Of Polycythemia Vera: An Update On Health-Related Quality Of Life And Patient-Reported Outcomes&lt;/p&gt;

Cingam, Shashank; Flatow-Trujillo, Lainey; Andritsos, Leslie A.; Yi, Cecilia Arana

doi:10.2147/jbm.s177692

Cited by 8 publications

(12 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, many patients are considered pruritis as the most upsetting symptom of PV, the same with our patient. [3,4,6] The pathophysiology of PV-associated pruritis is not wellunderstood. It was found that increased mast cells in the dermis are present in PV patients with pruritis; however, a similar number has been detected in patients without pruritis.…”

Section: Discussionmentioning

confidence: 99%

Ruxolitinib (a JAK2 inhibitor) as an emerging therapy for refractory pruritis in a patient with low-risk polycythemia vera

2021

View full text Add to dashboard Cite

Introduction: Polycythemia vera (PV) is a Philadelphia-negative myeloproliferative neoplasm (MPN) characterized by the overproduction of red blood cells. The presence of JAK2 mutation is detected in up to 99% of patients with PV. Pruritis is commonly encountered in patients with PV and is considered the most troublesome symptom. Multiple treatment modalities are used for treatment; however, their efficacy is variable. Sometimes, pruritis will not improve even by the use of combined therapies. Recently, Ruxolitinib (a JAK2 inhibitor) has been shown to be very effective, especially in patients with refractory pruritis in the setting of other treatment modalities failure.Patient concern: We describe a 55-year-old male with history of low risk PV presented with severe itching despite using different therapies, including phlebotomy and hydroxyurea. His laboratory results on presentation were significant for red blood cells (RBC) of 8.2 Â 10 6 /uL (normal = 4.5-5.5), hematocrit (Hct) of 52.8% (normal = 40-50%), platelet count of 519 Â 10 3 /uL (normal = 150-400), white blood cells count of 12.3 Â 10 3 /uL (normal = 4-10), and basophils count of 0.22 Â 10 3 /uL (normal < 0.1).

show abstract

Section: Discussionmentioning

confidence: 99%

Ruxolitinib (a JAK2 inhibitor) as an emerging therapy for refractory pruritis in a patient with low-risk polycythemia vera

2021

View full text Add to dashboard Cite

show abstract

“…Among JAK inhibitors, ruxolitinib is currently used in patients who suffer myelofibrosis. In this hematological condition, ruxolitinib can rapidly improve the patient's quality of life by reducing the secretion of pro-inflammatory cytokines, such as IL-1, TNF-α, IFN-γ, and IL-6 [158][159][160].…”

Section: Ruxolitinibmentioning

confidence: 99%

Pharmacological treatments of COVID-19

et al. 2020

View full text Add to dashboard Cite

The viral infection due to the new coronavirus or coronavirus disease 2019 (COVID-19), which was reported for the first time in December 2019, was named by the World Health Organization (WHO) as Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV2), because of the very similar genome and also its related symptoms to SARS-CoV1. The ongoing COVID-19 pandemic with significant mortality, morbidity, and socioeconomic impact is considered by the WHO as a global public health emergency. Since there is no specific treatment available for SARS-CoV2 infection, and or COVID-19, several clinical and sub-clinical studies are currently undertaken to find a gold-standard therapeutic regimen with high efficacy and low side effect. Based on the published scientific evidence published to date, we summarized herein the effects of different potential therapies and up-to-date clinical trials. The review is intended to help readers aware of potentially effective COVID-19 treatment and provide useful references for future studies.

show abstract

“…Vaccination to prevent reactivation of zoster is thus advocated prior to treatment [15,18]. Evidence-based medicine has revealed the favorable potential of ruxolitinib in PV, with alleviation of symptoms and improved patient-reported outcomes and quality of life [19]. A study to uncover the potential of momelotinib (a similar JAK inhibitor) in PV was also conducted but terminated due to low efficacy [20].…”

Section: Ruxolitinibmentioning

confidence: 99%

Advances in the Treatment of Polycythemia Vera: Trends in Disease Management

Arya

Syal

Gupta

et al. 2021

Cureus

View full text Add to dashboard Cite

Treatment modalities for polycythemia vera (PV) have evolved over time. Phlebotomy and low-dose aspirin suffice in low-risk patients, but cytoreductive therapies are indicated in all high-risk patients (age ≥ 65 years or those with a history of PV-related thrombotic event) and may be considered for low-risk patients with progressively increasing splenomegaly, progressively increasing leucocyte and platelet counts, and for those who do not tolerate phlebotomy. Hydroxyurea/hydroxycarbamide or interferons can be used as first-line drugs. Hydroxyurea may not be tolerated by some patients, and it also carries risk of myelosuppression. Interferon alfa is especially useful for PV symptoms, and the newer preparation, ropeginterferon alfa-2b, has lesser incidence of flu-like reactions. Ruxolitinib reduces the JAK2V617F mutation burden and is used as a second-line drug. Anagrelide reduces platelet production and can be used in conjunction with hydroxyurea in patients with excessive thrombocytosis. The alkylating agent, busulfan, can also be used as a last resort in patients with a limited life expectancy. Prospective future treatments include givinostat, a histone deacetylase inhibitor, and idasanutlin, a murine double minute 2 antagonist.

show abstract

<p>Ruxolitinib In The Treatment Of Polycythemia Vera: An Update On Health-Related Quality Of Life And Patient-Reported Outcomes</p>

Cited by 8 publications

References 35 publications

Ruxolitinib (a JAK2 inhibitor) as an emerging therapy for refractory pruritis in a patient with low-risk polycythemia vera

Ruxolitinib (a JAK2 inhibitor) as an emerging therapy for refractory pruritis in a patient with low-risk polycythemia vera

Pharmacological treatments of COVID-19

Advances in the Treatment of Polycythemia Vera: Trends in Disease Management

Contact Info

Product

Resources

About